Rules-Based Medicine (RBM), a Q² Solutions Company, is a CLIA-certified biomarker testing laboratory developing immunoassays used to quantify protein biomarkers in support of drug mechanism of action, pharmacodynamic, prognostic, and predictive clinical studies across all stages of drug discovery and development. RBM is the world’s leading multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture^®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (Simoa™) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.

What differentiates Rules-Based Medicine from its competitors is that they have spent over 20 years internally developing and manufacturing multiplex immunoassays validated to clinical laboratory standards for the Luminex xMAP^® technology. Since 2014, they have applied these skills to building ultrasensitive immunoassays on the Simoa™ platform to quantify protein biomarkers previously difficult or impossible to measure. The RBM platform appropriately combines Luminex and Simoa™ microsphere-based immunoassays with the precision and dependability of automated liquid handling systems, advanced quality monitoring, validated data reporting processes, and a highly trained and dedicated staff including project managers. Together these features set RBM apart from other biomarker testing laboratories by providing the highest quality, cost-effective approach to measuring biomarkers from a variety of biological samples.